Profile | Tagrisso (osimertinib) Connect

Tagrisso cardiotoxicity – an interesting case

Dr Arjun K Ghosh, Consultant Cardiologist, Barts Heart Centre and University College London Hospital

Tagrisso cardiotoxicity overview

Dr Arjun K Ghosh, Consultant Cardiologist, Barts Heart Centre and University College London Hospital

Stage IIB patient case study of adjuvant osimertinib

Dr Jason Chow, Consultant Medical Oncologist, St George’s Hospital

Severe reactions and warning signs

Dr David Rutkowski, Dermatology registrar and MRC clinical pharmacology fellow, NHS and University of Manchester

Introduction to EGFRi Skin toxicity

Dr David Rutkowski, Dermatology registrar and MRC clinical pharmacology fellow, NHS and University of Manchester

Management of skin toxicity

Dr David Rutkowski, Dermatology registrar and MRC clinical pharmacology fellow, NHS and University of Manchester

Tagrisso Case Study: First-Line EGFRm+ NSCLC – 45M

Dr Shobhit Baijal, Consultant Medical Oncologist, University Hospitals Birmingham

Tagrisso Case Study: First-line EGFRm+ NSCLC – 81F

Dr Ashley Cox, Consultant Clinical Oncologist Royal United Hospital Bath

Tagrisso Case Study: Second line EGFRm+ NSCLC – 63F

Dr David Woolf, Consultant Clinical Oncologist, Christie NHS Foundation Trust

Working with your patients to enhance their treatment pathway

Dr Gary Doherty, Consultant Medical Oncologist, Cambridge University Hospitals NHS Foundation Trust Ms Rachel Powell, Advanced Clinical Practitioner, University of Birmingham Hospitals NHS Foundation Trust

Tagrisso Case Study: First line EGFRm+ NSCLC – 84F

Dr Tom Newsom-Davis, Consultant Medical Oncologist, Chelsea and Westminster NHS Foundation Trust

Tagrisso Case Study: First line EGFRm+ NSCLC – 71F

Dr Tom Newsom-Davis, Consultant Medical Oncologist, Chelsea and Westminster NHS Foundation Trust

Tagrisso Case Study: First line EGFRm+ NSCLC – 76F

Dr David Woolf, Consultant Clinical Oncologist, Christie NHS Foundation Trust

Adjuvant setting case studies

Dr Marcus Remer, Consultant Medical Oncologist, Hampshire Hospitals NHS Foundation Trust

Adverse reactions reported	TAGRISSO		TAGRISSO with pemetrexed and platinum-based chemotherapy
Adverse reactions reported	CIOMS descriptor/ overall frequency (all CTCAE grades)	Frequency of CTCAE grade 3 or higher	CIOMS descriptor/ overall frequency (all CTCAE grades)	Frequency of CTCAE grade 3 or higher
Blood and lymphatic system disorders
Aplastic anaemia	Rare (0.06%)	0.06%	0%	0%
Leukopenia	Common (5.4%)	0.4%	Very common (12.7%)	2.9%
Lymphopenia	Common (1.7%)	0.2%	Common (2.5%)	1.1%
Thrombocytopenia	Common (7.6%)	0.6%	Very common (18.5%)	6.9%
Neutropenia	Common (6%)	0.9%	Very common (24.6%)	13.4%
Metabolism and nutrition disorders
Decreased appetite	Very common (19%)	1.2%	Very common (31%)	2.9%
Eye disorders
Keratitis	Uncommon (0.6%)	0.06%	Uncommon (0.7%)	0%
Cardiac disorders
Cardiac failure	Uncommon (0.5%)	0.2%	Common (1.8%)	1.1%
Respiratory, thoracic and mediastinal disorders
Epistaxis	Common (6%)	0%	Common (7%)	0.4%
Interstitial lung disease	Common (4.0%)	1.4%	Common (3.3%)	0.7%
Gastrointestinal disorders
Diarrhoea	Very common (47%)	1.4%	Very common (43%)	2.9%
Stomatitis	Very common (24%)	0.4%	Very common (31%)	0.4%
Skin and subcutaneous tissue disorders
Rash	Very common (46%)	0.8%	Very common (49%)	2.5%
Paronychia	Very common (34%)	0.4%	Very common (27%)	0.7%
Dry skin	Very common (32%)	0.1%	Very common (24%)	0%
Pruritus	Very common (17%)	0.06%	Common (8%)	0%
Alopecia	Common (5%)	0%	Common (9%)	0%
Palmar-plantar erythrodysaesthesia syndrome	Common (2.1%)	0%	Common (5%)	0%
Urticaria	Common (1.9%)	0.1%	Common (1.4%)	0.4%
Skin hyperpigmentation	Common (1.0%)	0%	Common (2.5%)	0%
Erythema multiforme	Uncommon (0.3%)	0%	Common (1.4%)	0.7%
Cutaneous vasculitis	Uncommon (0.2%)		0%	0%
Stevens-Johnson syndrome	Rare (0.02%)		0%	0%
Toxic Epidermal Necrolysis	Not known		0%	0%
Investigations
Left ventricular ejection fraction decreased	Common (4.2%)		Common (8%)
QTc interval prolongation	Common (1.1%)		Common (1.8%)
Blood creatine phosphokinase increased	Common (1.9%)	0.3%	Common (3.3%)	1.1%
Investigations (Findings based on test results presented as CTCAE grade shifts)
Leucocytes decreased	Very common (65%)	1.8%	Very common (88%)	20%
Lymphocytes decreased	Very common (64%)	8%	Very common (78%)	16%
Platelet count decreased	Very common (53%)	1.3%	Very common (85%)	16%
Neutrophils decreased	Very common (36%)	4.0%	Very common (85%)	36%
Blood creatinine increased	Common (9%)	0.2%	Very common (22%)	0.4%
Musculoskeletal and connective tissue disorders
Myositis	Uncommon (0.2%)	0%	0%	0%

Tagrisso Case Studies